Objective
Lung cancer is a leading cause of cancer deaths in Europe. Non small cell lung cancer (NSCLC) accounts for nearly 85% of all cases of lung cancer with a five year survival rate of 15%. Novel targeted therapies are urgently needed to overcome drug resistance and prevent tumour recurrence. The host supervisor carried out a small molecule screen to identify therapeutics for the treatment of drug-resistant NSCLC. A novel specific inhibitor of histone deacetylase 6 (HDAC6) was discovered. The molecular mechanisms of HDAC6's role in cancer is beginning to be elucidated however, this task is made difficult due to the lack of a specific inhibitor. The overall research aim of this proposal is to understand the molecular mechanisms of HDAC6 in the tumour initiation and progression of NSCLC. To do this, I will develop a unique state-of-the-art conditional genetic mouse model of NSCLC in which HDAC6 is knocked out. I will do this work in the laboratory of Prof. Wong at New York University, an expert in conditional genetic mouse models. I will study the role of HDAC6 on the immune-microenvironment of the lung tumours using multi-parameter flow cytometry and single cell RNA-sequencing. Upon re-integration to the host laboratory I will establish the HDAC6 knockout NSCLC mouse model. Lastly, I will assess the efficacy of the novel HDAC6 inhibitor on tumour progression compared to the mouse model. This project has the potential to contribute greatly to our understanding of the role of HDAC6 in NSCLC and lead to the discovery of targeted therapeutic. Through this prestigious fellowship I will diversify my research skill-set, I will gain international experience in a world-leading laboratory of NSCLC and I will be excellently positioned to develop my independent research career on return to Europe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology lung cancer
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2 DUBLIN
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.